companies / aptatargets-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 7,000,0007.0M | ○ |
|---|---|---|
| founded | 2014 | |
| hq | Madrid, Spain | |
| industry | unknown | |
| stage | null |
aptaTargets is a clinical-stage biopharmaceutical developing aptamer-based therapeutics targeting acute inflammatory conditions like ischemic stroke. It serves patients suffering from stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis. Its lead candidate ApTOLL is the only drug in development that treats stroke by blocking TLR4 activation, a neuroprotective mechanism now licensed to Merck.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-04-01 | grant | 2,700,0002.7M | null | ○ |
Nginx 1.29.2, Yoast SEO 13.2, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 1.4.1, DoubleClick Floodlight, React, PHP, MySQL, wordpress ., jquery 1.1
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |